Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 39

1.

Nasal gene expression changes with inhaled corticosteroid treatment in asthma.

Boudewijn IM, Lan A, Faiz A, Cox CA, Brouwer S, Schokker S, Vroegop SJ, Nawijn MC, Woodruff PG, Christenson SA, Hagedoorn P, Frijlink HW, Choy DF, Brouwer U, Wisman M, Postma DS, Fingleton J, Beasley R, van den Berge M, Guryev V.

Allergy. 2019 Jun 22. doi: 10.1111/all.13952. [Epub ahead of print] No abstract available.

PMID:
31230369
2.
3.

A randomised pragmatic trial of corticosteroid optimization in severe asthma using a composite biomarker algorithm to adjust corticosteroid dose versus standard care: study protocol for a randomised trial.

Hanratty CE, Matthews JG, Arron JR, Choy DF, Pavord ID, Bradding P, Brightling CE, Chaudhuri R, Cowan DC, Djukanovic R, Gallagher N, Fowler SJ, Hardman TC, Harrison T, Holweg CT, Howarth PH, Lordan J, Mansur AH, Menzies-Gow A, Mosesova S, Niven RM, Robinson DS, Shaw DE, Walker S, Woodcock A, Heaney LG; RASP-UK (Refractory Asthma Stratification Programme) Consortium.

Trials. 2018 Jan 4;19(1):5. doi: 10.1186/s13063-017-2384-7.

4.

IFN-stimulated Gene Expression, Type 2 Inflammation, and Endoplasmic Reticulum Stress in Asthma.

Bhakta NR, Christenson SA, Nerella S, Solberg OD, Nguyen CP, Choy DF, Jung KL, Garudadri S, Bonser LR, Pollack JL, Zlock LT, Erle DJ, Langelier C, Derisi JL, Arron JR, Fahy JV, Woodruff PG.

Am J Respir Crit Care Med. 2018 Feb 1;197(3):313-324. doi: 10.1164/rccm.201706-1070OC.

5.

High density lipoproteins and type 2 inflammatory biomarkers are negatively correlated in atopic asthmatics.

Barochia AV, Gordon EM, Kaler M, Cuento RA, Theard P, Figueroa DM, Yao X, Weir NA, Sampson ML, Stylianou M, Choy DF, Holweg CTJ, Remaley AT, Levine SJ.

J Lipid Res. 2017 Aug;58(8):1713-1721. doi: 10.1194/jlr.P077776. Epub 2017 Jun 27.

6.

Increased Autophagy-Related 5 Gene Expression Is Associated with Collagen Expression in the Airways of Refractory Asthmatics.

Poon AH, Choy DF, Chouiali F, Ramakrishnan RK, Mahboub B, Audusseau S, Mogas A, Harris JM, Arron JR, Laprise C, Hamid Q.

Front Immunol. 2017 Mar 29;8:355. doi: 10.3389/fimmu.2017.00355. eCollection 2017.

7.

Accurately measuring and modeling Th2 and Th17 endotypes in severe asthma.

Hart KM, Choy DF, Bradding P, Wynn TA, Arron JR.

Ann Transl Med. 2017 Feb;5(4):91. doi: 10.21037/atm.2017.02.07. No abstract available.

8.

A CEACAM6-High Airway Neutrophil Phenotype and CEACAM6-High Epithelial Cells Are Features of Severe Asthma.

Shikotra A, Choy DF, Siddiqui S, Arthur G, Nagarkar DR, Jia G, Wright AK, Ohri CM, Doran E, Butler CA, Hargadon B, Abbas AR, Jackman J, Wu LC, Heaney LG, Arron JR, Bradding P.

J Immunol. 2017 Apr 15;198(8):3307-3317. doi: 10.4049/jimmunol.1600606. Epub 2017 Mar 8.

9.

Seasonal variability of severe asthma exacerbations and clinical benefit from lebrikizumab.

Staton TL, Arron JR, Olsson J, Holweg CTJ, Matthews JG, Choy DF.

J Allergy Clin Immunol. 2017 May;139(5):1682-1684.e3. doi: 10.1016/j.jaci.2017.01.028. Epub 2017 Feb 24. No abstract available.

PMID:
28238745
10.

Depletion of major pathogenic cells in asthma by targeting CRTh2.

Huang T, Hazen M, Shang Y, Zhou M, Wu X, Yan D, Lin Z, Solon M, Luis E, Ngu H, Shi Y, Katewa A, Choy DF, Ramamoorthi N, Castellanos ER, Balazs M, Xu M, Lee WP, Matsumoto ML, Payandeh J, Arron JR, Hongo JA, Wang J, Hötzel I, Austin CD, Reif K.

JCI Insight. 2016 May 19;1(7):e86689. doi: 10.1172/jci.insight.86689.

11.

Peripheral blood gene expression predicts clinical benefit from anti-IL-13 in asthma.

Choy DF, Jia G, Abbas AR, Morshead KB, Lewin-Koh N, Dua R, Rivera P, Moonsamy P, Fontecha M, Balasubramanyam A, Santini C, Bassett E, Ray JM, Cabanski CR, Bradley MS, Maciuca R, Mosesova S, Scheerens H, Arron JR.

J Allergy Clin Immunol. 2016 Oct;138(4):1230-1233.e8. doi: 10.1016/j.jaci.2016.06.008. Epub 2016 Jun 29. No abstract available.

PMID:
27474124
12.

Reduced epithelial suppressor of cytokine signalling 1 in severe eosinophilic asthma.

Doran E, Choy DF, Shikotra A, Butler CA, O'Rourke DM, Johnston JA, Kissenpfennig A, Bradding P, Arron JR, Heaney LG.

Eur Respir J. 2016 Sep;48(3):715-25. doi: 10.1183/13993003.00400-2015. Epub 2016 Jun 23.

13.

Biomarkers in the clinical development of asthma therapies.

Staton TL, Choy DF, Arron JR.

Biomark Med. 2016;10(2):165-76. doi: 10.2217/bmm.15.116. Epub 2016 Jan 14. Review.

PMID:
26764286
14.

Inhibition of the kinase ITK in a mouse model of asthma reduces cell death and fails to inhibit the inflammatory response.

Sun Y, Peng I, Webster JD, Suto E, Lesch J, Wu X, Senger K, Francis G, Barrett K, Collier JL, Burch JD, Zhou M, Chen Y, Chan C, Eastham-Anderson J, Ngu H, Li O, Staton T, Havnar C, Jaochico A, Jackman J, Jeet S, Riol-Blanco L, Wu LC, Choy DF, Arron JR, McKenzie BS, Ghilardi N, Ismaili MH, Pei Z, DeVoss J, Austin CD, Lee WP, Zarrin AA.

Sci Signal. 2015 Dec 1;8(405):ra122. doi: 10.1126/scisignal.aab0949.

PMID:
26628680
15.

TH2 and TH17 inflammatory pathways are reciprocally regulated in asthma.

Choy DF, Hart KM, Borthwick LA, Shikotra A, Nagarkar DR, Siddiqui S, Jia G, Ohri CM, Doran E, Vannella KM, Butler CA, Hargadon B, Sciurba JC, Gieseck RL, Thompson RW, White S, Abbas AR, Jackman J, Wu LC, Egen JG, Heaney LG, Ramalingam TR, Arron JR, Wynn TA, Bradding P.

Sci Transl Med. 2015 Aug 19;7(301):301ra129. doi: 10.1126/scitranslmed.aab3142.

PMID:
26290411
16.

The airway microbiome in patients with severe asthma: Associations with disease features and severity.

Huang YJ, Nariya S, Harris JM, Lynch SV, Choy DF, Arron JR, Boushey H.

J Allergy Clin Immunol. 2015 Oct;136(4):874-84. doi: 10.1016/j.jaci.2015.05.044. Epub 2015 Jul 26.

17.

Research in progress: Medical Research Council United Kingdom Refractory Asthma Stratification Programme (RASP-UK).

Heaney LG, Djukanovic R, Woodcock A, Walker S, Matthews JG, Pavord ID, Bradding P, Niven R, Brightling CE, Chaudhuri R, Arron JR, Choy DF, Cowan D, Mansur A, Menzies-Gow A, Adcock I, Chung KF, Corrigan C, Coyle P, Harrison T, Johnston S, Howarth P, Lordan J, Sabroe I, Bigler J, Smith D, Catley M, May R, Pierre L, Stevenson C, Crater G, Keane F, Costello RW, Hudson V, Supple D, Hardman T.

Thorax. 2016 Feb;71(2):187-9. doi: 10.1136/thoraxjnl-2015-207326. Epub 2015 Jul 23. Review.

18.

IL-13 mediates IL-33-dependent mast cell and type 2 innate lymphoid cell effects on bronchial epithelial cells.

Nagarkar DR, Ramirez-Carrozzi V, Choy DF, Lee K, Soriano R, Jia G, Abbas AR, Modrusan Z, Pappu R, Arron JR.

J Allergy Clin Immunol. 2015 Jul;136(1):202-5. doi: 10.1016/j.jaci.2015.01.036. Epub 2015 Mar 14. No abstract available.

PMID:
25784274
19.

A microRNA upregulated in asthma airway T cells promotes TH2 cytokine production.

Simpson LJ, Patel S, Bhakta NR, Choy DF, Brightbill HD, Ren X, Wang Y, Pua HH, Baumjohann D, Montoya MM, Panduro M, Remedios KA, Huang X, Fahy JV, Arron JR, Woodruff PG, Ansel KM.

Nat Immunol. 2014 Dec;15(12):1162-70. doi: 10.1038/ni.3026. Epub 2014 Nov 2.

20.

Synovial phenotypes in rheumatoid arthritis correlate with response to biologic therapeutics.

Dennis G Jr, Holweg CT, Kummerfeld SK, Choy DF, Setiadi AF, Hackney JA, Haverty PM, Gilbert H, Lin WY, Diehl L, Fischer S, Song A, Musselman D, Klearman M, Gabay C, Kavanaugh A, Endres J, Fox DA, Martin F, Townsend MJ.

Arthritis Res Ther. 2014;16(2):R90. Epub 2014 Apr 30.

21.

Interleukin-18 has antipermeablity and antiangiogenic activities in the eye: reciprocal suppression with VEGF.

Shen J, Choy DF, Yoshida T, Iwase T, Hafiz G, Xie B, Hackett SF, Arron JR, Campochiaro PA.

J Cell Physiol. 2014 Aug;229(8):974-83. doi: 10.1002/jcp.24575.

22.

Noninvasive biomarkers that predict treatment benefit from biologic therapies in asthma.

Arron JR, Choy DF, Scheerens H, Matthews JG.

Ann Am Thorac Soc. 2013 Dec;10 Suppl:S206-13. doi: 10.1513/AnnalsATS.201303-047AW. Review.

PMID:
24313774
23.

Disconnect between sputum neutrophils and other measures of airway inflammation in asthma.

Arron JR, Choy DF, Laviolette M, Kelsen SG, Hatab A, Leigh R, Thomson NC, Bleecker ER, Olivenstein R, Avila PC, Jarjour NN, Castro M, Gauvreau GM, Good JT, Kline JN, Mansur A, Mayers I, Heaney LG, Hamid Q, Harris JM.

Eur Respir J. 2014 Feb;43(2):627-9. doi: 10.1183/09031936.00117013. Epub 2013 Oct 31. No abstract available.

24.

The effects of lebrikizumab in patients with mild asthma following whole lung allergen challenge.

Scheerens H, Arron JR, Zheng Y, Putnam WS, Erickson RW, Choy DF, Harris JM, Lee J, Jarjour NN, Matthews JG.

Clin Exp Allergy. 2014 Jan;44(1):38-46. doi: 10.1111/cea.12220.

25.

Exploring the effects of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA study.

Hanania NA, Wenzel S, Rosén K, Hsieh HJ, Mosesova S, Choy DF, Lal P, Arron JR, Harris JM, Busse W.

Am J Respir Crit Care Med. 2013 Apr 15;187(8):804-11. doi: 10.1164/rccm.201208-1414OC.

PMID:
23471469
26.

Comparative transcriptomic analyses of atopic dermatitis and psoriasis reveal shared neutrophilic inflammation.

Choy DF, Hsu DK, Seshasayee D, Fung MA, Modrusan Z, Martin F, Liu FT, Arron JR.

J Allergy Clin Immunol. 2012 Dec;130(6):1335-43.e5. doi: 10.1016/j.jaci.2012.06.044. Epub 2012 Aug 22.

27.

Periostin is a systemic biomarker of eosinophilic airway inflammation in asthmatic patients.

Jia G, Erickson RW, Choy DF, Mosesova S, Wu LC, Solberg OD, Shikotra A, Carter R, Audusseau S, Hamid Q, Bradding P, Fahy JV, Woodruff PG, Harris JM, Arron JR; Bronchoscopic Exploratory Research Study of Biomarkers in Corticosteroid-refractory Asthma (BOBCAT) Study Group.

J Allergy Clin Immunol. 2012 Sep;130(3):647-654.e10. doi: 10.1016/j.jaci.2012.06.025. Epub 2012 Aug 1.

28.

Pretreatment synovial transcriptional profile is associated with early and late clinical response in rheumatoid arthritis patients treated with rituximab.

Hogan VE, Holweg CT, Choy DF, Kummerfeld SK, Hackney JA, Teng YK, Townsend MJ, van Laar JM.

Ann Rheum Dis. 2012 Nov;71(11):1888-94. doi: 10.1136/annrheumdis-2011-201115. Epub 2012 Jun 26.

PMID:
22736099
29.

Glucocorticoid receptor β and histone deacetylase 1 and 2 expression in the airways of severe asthma.

Butler CA, McQuaid S, Taggart CC, Weldon S, Carter R, Skibinski G, Warke TJ, Choy DF, McGarvey LP, Bradding P, Arron JR, Heaney LG.

Thorax. 2012 May;67(5):392-8. doi: 10.1136/thoraxjnl-2011-200760. Epub 2011 Dec 8.

PMID:
22156779
30.

Increased expression of immunoreactive thymic stromal lymphopoietin in patients with severe asthma.

Shikotra A, Choy DF, Ohri CM, Doran E, Butler C, Hargadon B, Shelley M, Abbas AR, Austin CD, Jackman J, Wu LC, Heaney LG, Arron JR, Bradding P.

J Allergy Clin Immunol. 2012 Jan;129(1):104-11.e1-9. doi: 10.1016/j.jaci.2011.08.031. Epub 2011 Oct 5.

PMID:
21975173
31.

Lung gene expression in a rhesus allergic asthma model correlates with physiologic parameters of disease and exhibits common and distinct pathways with human asthma and a mouse asthma model.

Abbas AR, Jackman JK, Bullens SL, Davis SM, Choy DF, Fedorowicz G, Tan M, Truong BT, Gloria Meng Y, Diehl L, Miller LA, Schelegle ES, Hyde DM, Clark HF, Modrusan Z, Arron JR, Wu LC.

Am J Pathol. 2011 Oct;179(4):1667-80. doi: 10.1016/j.ajpath.2011.06.009. Epub 2011 Aug 3.

32.

Gene expression patterns of Th2 inflammation and intercellular communication in asthmatic airways.

Choy DF, Modrek B, Abbas AR, Kummerfeld S, Clark HF, Wu LC, Fedorowicz G, Modrusan Z, Fahy JV, Woodruff PG, Arron JR.

J Immunol. 2011 Feb 1;186(3):1861-9. doi: 10.4049/jimmunol.1002568. Epub 2010 Dec 27.

33.

Monitoring ocular drug therapy by analysis of aqueous samples.

Campochiaro PA, Choy DF, Do DV, Hafiz G, Shah SM, Nguyen QD, Rubio R, Arron JR.

Ophthalmology. 2009 Nov;116(11):2158-64. doi: 10.1016/j.ophtha.2009.04.038. Epub 2009 Aug 22.

PMID:
19700195
34.

T-helper type 2-driven inflammation defines major subphenotypes of asthma.

Woodruff PG, Modrek B, Choy DF, Jia G, Abbas AR, Ellwanger A, Koth LL, Arron JR, Fahy JV.

Am J Respir Crit Care Med. 2009 Sep 1;180(5):388-95. doi: 10.1164/rccm.200903-0392OC. Epub 2009 May 29. Erratum in: Am J Respir Crit Care Med. 2009 Oct 15;180(8):796.

35.

A dual-labeling method to quantify unscheduled DNA synthesis in primary cells.

Li W, Choy DF, Post JM, Sullivan ME.

J Pharmacol Toxicol Methods. 2008 May-Jun;57(3):220-6. doi: 10.1016/j.vascn.2007.12.003. Epub 2008 Jan 17.

PMID:
18396065
36.

Ranibizumab for macular edema due to retinal vein occlusions: implication of VEGF as a critical stimulator.

Campochiaro PA, Hafiz G, Shah SM, Nguyen QD, Ying H, Do DV, Quinlan E, Zimmer-Galler I, Haller JA, Solomon SD, Sung JU, Hadi Y, Janjua KA, Jawed N, Choy DF, Arron JR.

Mol Ther. 2008 Apr;16(4):791-9. doi: 10.1038/mt.2008.10. Epub 2008 Feb 5.

37.

Angiotensin II induces histomorphologic features of unstable plaque in a murine model of accelerated atherosclerosis.

da Cunha V, Martin-McNulty B, Vincelette J, Choy DF, Li WW, Schroeder M, Mahmoudi M, Halks-Miller M, Wilson DW, Vergona R, Sullivan ME, Wang YX.

J Vasc Surg. 2006 Aug;44(2):364-71.

38.

Inhibition of Rho-kinase by fasudil attenuated angiotensin II-induced cardiac hypertrophy in apolipoprotein E deficient mice.

Wang YX, da Cunha V, Martin-McNulty B, Vincelette J, Li W, Choy DF, Halks-Miller M, Mahmoudi M, Schroeder M, Johns A, Light DR, Dole WP.

Eur J Pharmacol. 2005 Apr 11;512(2-3):215-22.

PMID:
15840407
39.

Use of cultured cells of kidney origin to assess specific cytotoxic effects of nephrotoxins.

Li W, Choy DF, Lam MS, Morgan T, Sullivan ME, Post JM.

Toxicol In Vitro. 2003 Feb;17(1):107-13.

PMID:
12537968

Supplemental Content

Support Center